US FDA Launches Study Of Prescriber Perceptions About Abuse-Deterrent Opioids
The agency is assessing whether to use different language to describe addiction and abuse deterrence.
You may also be interested in...
FDA advisory committee members raise concerns about inappropriate marketing and prescribing practices.
"Incremental" step forward is sufficient for product to be labeled as deterring abuse by nasal, but not intravenous route, advisory committee members conclude.
Our infographic illustrates the recommendations in FDA’s COVID-19 pandemic recovery and preparedness plan, ranging from strengthening the EUA process to managing the backlog of pending inspections.